---
title: "BofAS: JD HEALTH  Faces Operational Volatility in 3Q but Structural Growth Remains Intact"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305911692.md"
description: "BofA Securities maintains a 'Buy' rating on JD Health with a HKD57 target price, citing intact structural growth despite Q3 operational volatility. While Q3 revenue rose 17% YoY, the broker lowered full-year revenue growth forecasts to 15% due to regulatory scrutiny and high base effects in Q4. Adjusted operating profit and net profit growth forecasts remain at 31% and 6% respectively, reflecting expected margin expansion from economies of scale and supply chain efficiency."
datetime: "2026-11-18T04:08:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305911692.md)
  - [en](https://longbridge.com/en/news/305911692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305911692.md)
generator: "portal-rs"
---

# BofAS: JD HEALTH  Faces Operational Volatility in 3Q but Structural Growth Remains Intact

BofA Securities published a research report stating that JD HEALTH (06618.HK) -7.260 (-17.613%) Short selling $90.55M; Ratio 21.577% experienced operational volatility in 3Q, but its structural growth remains intact. Its 3Q revenue rose 17% YoY, beating expectations, with revenue growth improving from 15% in 2Q. Structural growth remains intact. The broker reiterated its "Buy" rating and maintained its TP at HKD57.

However, considering the impact of regulatory scrutiny on misleading promotions by major brands in the nutrition and healthcare supplements industry, as well as the high comparison base for the pharmaceutical segment due to influenza in 4Q last year, BofA Securities expects JD HEALTH's revenue growth to slow in 4Q. It lowered its full-year revenue growth forecast from 16% to 15%, while maintaining forecasts for adjusted operating profit and net profit growth of 31% YoY and 6% YoY respectively. The broker still believes JD HEALTH's earnings are resilient and can benefit from economies of scale, supply chain efficiency, pharmaceutical margins and operational efficiency, with margins expected to continue expanding.

The broker also slightly lowered its 2026 EPS forecast from RMB2.17 to RMB2.16, while slightly raising its 2027 EPS forecast from RMB2.51 to RMB2.52.(gc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)

### Related Stocks

- [06618.HK](https://longbridge.com/en/quote/06618.HK.md)
- [86618.HK](https://longbridge.com/en/quote/86618.HK.md)

## Related News & Research

- [JD Health Trustee Purchases Shares for Post-IPO Award Scheme](https://longbridge.com/en/news/306036144.md)
- [BofAS Cuts JD HEALTH TP to HKD57; 1H Earnings Beat](https://longbridge.com/en/news/295915379.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**